Abstract Title

Combination Therapy with Short-Contact Topical Calcipotriene and 5-FU For Actinic Keratosis

Presenter Name

Madalyn Nguyen

RAD Assignment Number

2002

Abstract

Background: Actinic keratoses (AKs) are precursor lesions to squamous cell carcinoma that arise from dysplasia of keratinocytes, which is enhanced by long-term ultraviolet radiation exposure. Treatment of actinic keratoses has traditionally involved cryotherapy, or various topical therapies such as topical 5-fluorouracil (5-FU) monotherapy, or combination therapy with cryotherapy. Because of irritation with use of topical 5-FU, short-contact therapy with 5-FU in combination with cryotherapy has been reported. Vitamin D derivatives have also been reported as systemic anti-cancer agents, though clinical data for usage is limited mainly due to hypercalcemia as an adverse effect and dose-limiting factor. Recent research has suggested that topical Vitamin D derivatives such as calcipotriene may be safe and efficacious agents for the treatment of AKs.

Objective: The aim of this study was to evaluate efficacy and safety of short-contact topical treatment with calcipotriene and 5-FU with cryotherapy in the treatment of AKs. Combination short-contact calcipotriene and 5-FU with cryotherapy will be compared to short-contact 5-FU with cryotherapy and cryotherapy alone to determine differences in efficacy and safety between the treatment modalities.

Methods: Subjects were identified as eligible for inclusion in this study based on a clinical diagnosis of actinic keratosis and treatment with cryotherapy, 5-FU, and/or topical calcipotriene between 2016 to 2018. The patients were divided into three treatment groups: 1) short-contact combination treatment with calcipotriene and 5-FU with cryotherapy, 2) short-contact 5-FU and cryotherapy, and 3) cryotherapy alone. Patients were assessed for baseline lesions in the face, scalp, upper extremities, chest, back, and lower extremities, and again at 1 month follow-up, 3 months follow-up, and 6 months follow-up. An analysis of covariance (ANCOVA) model with terms for treatment and baseline lesion count as covariate was used to compare post-treatment lesion count between treatment groups estimated at 95% confidence intervals (95% CI).

Results: Data was collected on 50 patients in each subset. After adjusting for imbalances in baseline count, a statistically significant reduction in number of AK lesions occured after 6 months of treatment with short-contact combination treatment with calcipotriene and 5-FU with cryotherapy in comparison to short-contact 5-FU with cryotherapy and to cryotherapy. The mean total lesion count at month 6 in the short-contact combination treatment with calcipotriene and 5-FU with cryotherapy was significantly lower than in the other 2 subsets.

Conclusions: Addition of topical calcipotriene to short-contact combination treatment of topical 5-FU with cryotherapy may result in improved long-term outcomes for patients with actinic keratoses. Larger series must be done to confirm increased efficacy and safety.

Is your abstract for competition or not for competition?

Competition

Research Area

Pharmacology

Presentation Type

Poster

This document is currently not available here.

Share

COinS
 

Combination Therapy with Short-Contact Topical Calcipotriene and 5-FU For Actinic Keratosis

Background: Actinic keratoses (AKs) are precursor lesions to squamous cell carcinoma that arise from dysplasia of keratinocytes, which is enhanced by long-term ultraviolet radiation exposure. Treatment of actinic keratoses has traditionally involved cryotherapy, or various topical therapies such as topical 5-fluorouracil (5-FU) monotherapy, or combination therapy with cryotherapy. Because of irritation with use of topical 5-FU, short-contact therapy with 5-FU in combination with cryotherapy has been reported. Vitamin D derivatives have also been reported as systemic anti-cancer agents, though clinical data for usage is limited mainly due to hypercalcemia as an adverse effect and dose-limiting factor. Recent research has suggested that topical Vitamin D derivatives such as calcipotriene may be safe and efficacious agents for the treatment of AKs.

Objective: The aim of this study was to evaluate efficacy and safety of short-contact topical treatment with calcipotriene and 5-FU with cryotherapy in the treatment of AKs. Combination short-contact calcipotriene and 5-FU with cryotherapy will be compared to short-contact 5-FU with cryotherapy and cryotherapy alone to determine differences in efficacy and safety between the treatment modalities.

Methods: Subjects were identified as eligible for inclusion in this study based on a clinical diagnosis of actinic keratosis and treatment with cryotherapy, 5-FU, and/or topical calcipotriene between 2016 to 2018. The patients were divided into three treatment groups: 1) short-contact combination treatment with calcipotriene and 5-FU with cryotherapy, 2) short-contact 5-FU and cryotherapy, and 3) cryotherapy alone. Patients were assessed for baseline lesions in the face, scalp, upper extremities, chest, back, and lower extremities, and again at 1 month follow-up, 3 months follow-up, and 6 months follow-up. An analysis of covariance (ANCOVA) model with terms for treatment and baseline lesion count as covariate was used to compare post-treatment lesion count between treatment groups estimated at 95% confidence intervals (95% CI).

Results: Data was collected on 50 patients in each subset. After adjusting for imbalances in baseline count, a statistically significant reduction in number of AK lesions occured after 6 months of treatment with short-contact combination treatment with calcipotriene and 5-FU with cryotherapy in comparison to short-contact 5-FU with cryotherapy and to cryotherapy. The mean total lesion count at month 6 in the short-contact combination treatment with calcipotriene and 5-FU with cryotherapy was significantly lower than in the other 2 subsets.

Conclusions: Addition of topical calcipotriene to short-contact combination treatment of topical 5-FU with cryotherapy may result in improved long-term outcomes for patients with actinic keratoses. Larger series must be done to confirm increased efficacy and safety.